Loading the records…
Loading the records…
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, Powl Brian T., holds the title of Chief Commercial Officer at Kura Oncology, Inc..
On 2026-11-19, the insider transacted 448 shares.The shares were transacted at a weighted average price of $7.27 per share, resulting in a total market-relevant value of $3K.
Powl Brian T. (Chief Commercial Officer) sold $3K of $KURA
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.